The Acinetobacter Nightmare: Mechanisms and Clinical Implications
|
|
- Dylan Flowers
- 5 years ago
- Views:
Transcription
1 The Acinetobacter Nightmare: Mechanisms and Clinical Implications Yohei Doi, MD, PhD University of Pittsburgh Fujita Health University Antimicrobial Resistance Research and Stewardship Conference January 17, 2018
2 Disclosures Advisory Board Meiji Roche The Medicines Company Research Grant Accelerate Diagnostics Clinical trials Shionogi
3 Objectives Understand trends in antimicrobial susceptibility of Acinetobacter baumannii Review the key resistance mechanisms Review new treatment modalities in the pipeline
4 Introduction Acinetobacter spp. A group of genetically related non-lactose-fermenting, oxidase-negative, gram-negative coccobacilli Most species are environmental and non-pathogenic Acinetobacter baumannii complex The clinically significant group of species that includes four genomospecies
5 Species identification Acinetobacter spp. Biochemical methods (e.g. MicroScan) MALDI-TOF (e.g. BioTyper) Acinetobacter baumannii complex Acinetobacter lwoffii Acinetobacter radioresistens Acinetobacter baumannii Acinetobacter nosocomialis Acinetobacter pittii Acinetobacter calcoaceticus Most clinically significant Most pathogenic among Acinetobacter spp. Tends to be drug-resistant
6 Clinical relevance A. baumannii causes Ventilator-associated pneumonia Bacteremia Wound infection Risk factors Antibiotic use (especially carbapenems) Catheters (intravenous, urinary) Severity of illness Duration of hospital stay ICU stay Doi Y, et al. Semin Respir Crit Care Med 2015;36:85
7 Clinical relevance Outbreaks are difficult to control Resistance to desiccation Aerosolization Antimicrobial resistance
8 Clinical relevance A. baumannii is extremely desiccation-resistant 1E+11 1E+10 1E Log of CFU/mL Bethany Townsend, unpublished data 0 (Wet) 0 (Dry) Days A2 T25987 A3 W34637 D4 M D5 F F8 S F9 W ATCC ATCC E. coli S. aureus P. aeruginosa K. pneumoniae A. baumannii IC2
9 Clinical relevance A. baumannii can aerosolize Trauma ICU in a Florida hospital with a longitudinal outbreak 11/21 (52.4%) of air cultures grew A. baumannii in rooms occupied by A. baumannii-positive patients 0/25 for A. baumannii-negative patients (p < ) Munoz-Price LS, et al. Crit Care Med 2013;41:1915
10 Clinical relevance A. baumannii ranked 5th as the causative organism of ventilator-associated pneumonia (6.6%) in ; its rank dropped to below 15th in VAP pathogens VAP pathogens Sievert DM, et al. Infect Control Hosp Epidemiol 2013;34:1 Weiner LM, et al. Infect Control Hosp Epidemiol 2016;37:1288
11 Evolution of resistance in A. baumannii A. baumannii was not always MDR/XDR Herellea vaginicola Early 1970s treated successfully with gentamicin, minocycline, nalidixic acid, ampicillin, or carbenicillin By early 1990s many are resistant to aminopenicillins, ureidopenicillins, cephalosporins, most aminoglycosides Imipenem remains the most active drug Outbreak of imipenem-resistant A. baumannii in Queens, NY Bergogne-Bérézin E, Towner KJ. Clin Microbiol Rev 1996;9:148 Go ES, et al. Lancet 1994;344:1329
12 International Clones predominate MDR is accounted for by International clones (ICs) 1, 2 and 3 Propagation of MDR in the 2000s likely represented replacement of indigenous strains by epidemic strains rather than evolution of existing strains Mera RM, et al. Microb Drug Resist. 2010;16:209 Karah N, et al. Drug Resist Updat. 2012;15:237-47
13 Bipolar susceptibilities Indigenous A. baumannii strain Epidemic A. baumannii strain
14 Antimicrobial susceptibility Antimicrobial susceptibility of ICU and non-icu clinical isolates in the U.S. ( ) ICU Non-ICU Sader HS, et al. Diagn Microbiol Infect Dis 2014;78:443
15 IC2 (CC2/CC92) 65 carbapenemnonsusceptible A. baumannii isolates Collected from 6 hospitals across the U.S. in (NY, PA, MO, FL, NV, CA) 24 PFGE clusters for 65 isolates By MLST, STs belonging to Clonal Complex (CC) 92/CC2 accounted for 55/65 isolates Adams-Haduch JM, et al. J Clin Microbiol 2011;49:3849
16 Resistance mechanisms A. baumannii is intrinsically resistant to antimicrobials Highly impermeable outer membranes 2-7-fold less permeable to cephalosporins than P. aeruginosa Efflux pumps MFS (major facilitator superfamily) and RND (resistance-nodulation-division) family
17 Efflux by Ade transporters RND family transporters of A. baumannii AdeABC Regulator = AdeRS (activator) Substrates = cephalosporins, carbapenem, aminoglycosides, fluoroquinolones, tigecycline AdeFGH Regulator = AdeL (activator-repressor) Substrates = fluoroquinolones, trimethoprim AdeIJK Regulator = AdeN (repressor) Substrates = cephalosporins, meropenem, fluoroquinolones, tigecycline Acquired resistance Intrinsic resistance Coyne S, et al. Antimicrob Agents Chemother 2011;55:947 Yoon EJ, et al. mbio 2015;6:e
18 β-lactamases of A. baumannii Intrinsic β-lactamases OXA-51 group Weak carbapenemases IC1 OXA-69 IC2 OXA-66 IC3 OXA-71 Modest contribution to carbapenem resistance ADC (AmpC) Cephalosporinase ADC-56 confers cefepime resistance Evans BA, et al. Clin Microbiol Infect 2008;14:268 Tian GB, et al. Antimicrob Agents Chemother 2011;55:4922
19 β-lactam resistance Acquired β-lactamases ESBLs (CTX-M, PER, GES) Acquired OXA carbapenemases Carbapenem resistance is largely mediated by production of acquired OXA carbapenemases OXA-23 OXA-40 OXA-58 OXA-143/253 OXA-235 bla OXA-23 ~78-kb plasmid Huang H, et al. J Antimicrob Chemother 2012;67:2825
20 Aminoglycoside resistance Efflux AdeABC Aminoglycoside-modifying enzymes AAC(6 )-Ib AAC(3)-Ia APH(3 )-IIb APH(3 )-VIa etc. 16S rrna methyltransferase ArmA Located on Tn6180 High-level GEN/TOB/AMK resistance Blackwell GA, et al. J Antimicrob Chemother 2017;72:1031
21 Fluoroquinolone resistance Efflux AdeABC AdeIJK QRDR mutations Quinolone Resistance Determining Regions GyrA: Ser83 Leu ParC: Ser80 Leu Likely working synergistically for high-level resistance Lopes BS, Amyes SG. Int J Antimicrob Agents 2013;41:117
22 How do we treat this? The standard approach at UPMC Presbyterian Hospital has been to treat infections with doripenem + colistin The combination is bactericidal in vitro 4/5 transplant patients survived infection with this this combination (as opposed to 1/11 with others) Shields RK, et al. Diagn Microbiol Infect Dis 2011;70:246
23 Colistin resistance Carbapenem-resistant infections are treated with colistin (typically in combinations) Cationic peptide which binds lipid A Colistin resistance is an emerging issue Global surveillance suggests % colistin resistance among XDR A. baumannii 65 A. baumannii VAP isolates Resistance rates (%) from Greece, Spain, Italy 48% resistance to colistin Flamm RK, et al. Diagn Microbiol Infect Dis 2016;85:352 Nowak J, et al. J Antimicrob Chemother 2017;72:3277
24 Colistin resistance Carbapnem/colistin-resistant infection cases Pt Underlying condition Type of infection Colistin Paired Survival therapy strains PFGE Colistin MIC 1 Lung transplant VAP Yes No Yes 0 2/>256 2 Heart transplant Mediastinitis Yes No Yes 0 1/>256 3 Lung transplant VAP Yes No Yes 0 1/>256 4 Respiratory failure VAP Yes Yes No Kidney transplant VAP Yes Yes Yes 0 2/4* 6 Respiratory failure VAP Yes Yes Yes 0 2/>256 7 Intracranial hemorrhage VAP Yes No Yes 0 2/>256 8 Cirrhosis VAP Yes No Yes 0 2/>256 9 Lung transplant VAP Yes Yes Yes 0 2/> Heart/lung transplant VAP Yes Yes Yes 1 2/> Liver transplant VAP Yes Yes Yes 0 2/> Lung transplant VAP Yes Yes Yes 6 2/> Cirrhosis colonization No No No Liver transplant bacteremia Yes Yes No - > Lung transplant VAP Yes Yes Yes 0 2/> Cerebral palsy VAP Yes No Yes 0 2/> Toxic epidermal necrolysis VAP Yes No No Intracranial hemorrhage VAP Yes Yes Yes 5 2/8 19 Stroke VAP Yes Yes Yes 1 2/ Lung transplant VAP Yes Yes Yes 1 2/16 21 Lung transplant VAP Yes Yes Yes /16
25 Colistin resistance Most were in ICU and had VAP; 28-day mortality = 30% Qureshi ZA, et al. Clin Infect Dis 2015;60:1295
26 Most isolates were carbapenemresistant and belonged to IC2 (CC2/CC92)
27 Colistin resistance Colistin resistance is due to modification of heptaacylated lipid A Phosphoethanolamine Colistin-susceptible Colistin-resistant
28 Colistin resistance Phosphoethanolamine modification is detected by mass spectrometry Intens. [a.u.] m/z=1910(heptaacyl lipid A) Intens. [a.u.] m/z=2034 (phosphoethanola mine added) m/z m/z Colistin-susceptible Colistin-resistant
29 Colistin resistance Addition of phosphoethanolamine is modulated by the pmrcab operon pmra = response regulator pmrb = sensor kinase pmrc = phosphoethanolamine transferase Associations have been made between specific mutations and resistance Beceiro A, et al. Antimicrob Agents Chemother 2011;55:3370 Arroyo LA, et al. Antimicrob Agents Chemother 2011;55:3743
30 Colistin resistance Complementation of each mutation indicates only some of reported mutations confer resistance The end result is lipid A modification by phosphoethanolamine Strain Colistin MIC µg/ml pmra (224 aa) Rec (aa 5-116) aa Amino acid mutations aa A4 >256 P190S pmrb (444 aa) HisK (aa ) aa HATPaseC (aa ) Red = confers resistance Blue = does not confer resistance 1E4 >256 A183T 1G2 >256 E186D 1A3 >256 Q227P 1H7 >256 P76L, R91S, T192I 2C9 32 P190T L249H 1A7 >256 L20F 1D5 128 M12I
31 Colistin resistance MALDI-TOF as a diagnostic tool? All A. baumannii complex isolates were prospectively collected at UPMC clinical microbiology laboratory for 3 years 451 isolates were identified as Acinetobacter spp. and subjected to: Genospecies identification (MALDI-TOF MS) Colistin susceptibility (microbroth MIC) Lipid A profile (MALDI-TOF MS)
32 Colistin resistance 451 A. baumannii complex isolates from 284 patients 362 A. baumannii 61 A. pittii 14 A. nosocomialis 6 A. calcoaceticus 3 non reliable ID 2 A. radioresistens 1 A. baylyi 1 A. guillouiae 1 A. junii 380 isolates from 245 patients -Susceptible by MIC -No PEtN peak 38 isolates from 17 patients -Non-susceptible by MIC -PEtN peak present 36 A. baumannii 1. A. pittii 1 A. nosocomialis 33 isolates from 21 patients -Unstable MICs -Unstable PEtN peak 29 A. baumannii 3 A. pittii 1 A. junii ~8% colistin resistance 100% sensitivity & specificity of MALDI-TOF in ID ing col-r
33 Treatment of A. baumannii infection We still know little Key agents Colistin Sulbactam Tigecycline Carbapenem Colistin + sulbactam + tigecycline? Network meta-analysis of MDR/XDR infections suggests so Colistin should be in the mix Tigecycline monotherapy to be avoided Kengkla K, et al. J Antimicrob Chemother 2018;73:22
34 Treatment of A. baumannii infection Outstanding questions regarding therapy: 1. Colistimethate (CMS) or polymyxin B? 2. Does nebulized CMS help for VAP? 3. How much sulbactam should one give? 4. Is there a role for double-dose tigecycline? 5. How about intravenous minocycline?
35 Treatment of A. baumannii infection Outstanding questions regarding therapy: 1. Colistimethate (CMS) or polymyxin B? 2. Does nebulized CMS help for VAP? 3. How much sulbactam should one give? 4. Is there a role for double-dose tigecycline? 5. How about intravenous minocycline?
36 Treatment options in the pipeline Many of the new agents are not active against A. baumannii Ceftolozane-tazobactam Ceftazidime-avibactam Meropenem-vaborbactam Plazomicin Ones with anti-a. baumannii activity Eravacycline Cefiderocol
37 Eravacycline Synthetic fluorocycline Highly active in vitro to A. baumannii Unique pharmacokinetics Eravacycline Minocycline MICs (mg/l) Tigecycline Connors KP, et al. Antimicrob Agents Chemother 2014;58:2113 Seifert H, et al. Int J Antimicrob Agents 2018;51:62
38 Cefiderocol Siderophore cephalosporin Highly active in vitro to A. baumannii Pharmacokinetically behaves as a β-lactam Katsube T, et al. J Clin Pharmacol 2017;57:584 Hackel MA, et al. Antimicrob Agents Chemother 2017;24:61:e
39 Engineered peptides Synthetic cationic antibiotic peptides Lead (WLBU2 = 24-mer) is more active than colistin against carbapenem-resistant bacteria including A. baumannii Also active against Gram-positives Gram-positives Gram-negatives Deslouches B, et al. Antimicrob Agents Chemother 2015;59:1329
40 Bacteriophage therapy Phage cocktail given to a patient on an eind basis Developed necrotizing pancreatitis while in Egypt and repatriated Treated with vancomycin, meroepenem, colistin, tigecycline Pseudocyst fluid grew MDR A. baumannii Treated with colistin, azithromycin Developed septic shock A cocktail of 4 anti-a. baumannii phages were given to the cavities, then intravenously for 59 days Schooley RT, et al. Antimicrob Agents Chemother 2017;61:e
41 Bacteriophage therapy He was discharged home 5 months later Caveats Minocycline was added while on bacteriophage therapy Resistance developed, necessitating change of the cocktail twice
42 In conclusion Acinetobacter baumannii continues to be a major cause of untreatable healthcare-associated infections Efflux and other class-specific resistance mechanisms contribute to multidrug resistance Specific epidemic clones predominate and should be the focus of research High-quality clinical data and trials are still scarce compared with other resistant pathogens of interest New treatment options are emerging, both close to clinic and early stage
43 Acknowledgments Laboratory Christi McElheny Roberta Mettus Sarah Bowler Caressa Spychala Jesabel Rivera Jessica O Hara Diana Pakstis Lloyd Clark University of Pittsburgh Vaughn Cooper Lee Harrison Mustapha Mustapha Ming Hong Nguyen Robert Shanks Andrew Nowalk Ryan Shields University of Maryland Robert Ernst Francesca Gardner Lisa Leung Courtney Chandler Leila Guerrero Lauren Hittle Funding National Institutes of Health Pennsylvania Department of Health
44
45 Number of publications PubMed search - carbapenem AND resistance AND (acinetobacter OR klebsiella[title]) Acinetobacter Klebsiella
Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationMulti-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes
Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationAcinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.
Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationAcinetobacter baumannii: from S to PDR
Acinetobacter baumannii: from S to PDR P. Plésiat French National Reference Center for Antibiotic Resistance University Hospital Jean Minjoz 25030 Besançon, France No conflict of interest! IDSA CID 2009,
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationAddressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationLearning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationGlobal Alliance for Infections in Surgery. Better understanding of the mechanisms of antibiotic resistance
Better understanding of the mechanisms of antibiotic resistance Antibiotic prescribing practices in surgery Contents Mechanisms of antibiotic resistance 4 Antibiotic resistance in Enterobacteriaceae 9
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationon April 8, 2018 by guest
AAC Accepted Manuscript Posted Online 9 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02252-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 Antimicrobial
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationThe impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationOvernight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationNon-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationHigh-Risk MDR clones news in treatment
Ferrara, 20 giugno 2013 High-Risk MDR clones news in treatment Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Characteristics and determinants of outcome of hospital-acquired
More informationGlobal Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016
Global Antibiotic Research and Development (GARD) Partnership Pasteur Institute DNDi Meeting February 29, 2016 Professor Visanu Thamlikitkul, MD Faculty of Medicine Siriraj Hospital, Mahidol University
More informationESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationImpact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital
Impact of Antimicrobial Resistance on Human Health Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital AMR in Foodchain Conference, UCD, Dec 2014 Sir Patrick Dun s Hospital
More informationResistant Gram-negative Bacteria
Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationManagement of hospital-acquired acquired pneumonia in the Asian Pacific region
Management of hospital-acquired acquired pneumonia in the Asian Pacific region Jae-Hoon Song, MD, PhD Samsung Medical Center Asian Network for Surveillance of Resistant Pathogens (ANSORP) Asian-Pacific
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationPharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens
Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More information10/15/08. Activity of an Antibiotic. Affinity for target. Permeability properties (ability to get to the target)
Beta-lactam antibiotics Penicillins Target - Cell wall - interfere with cross linking Actively growing cells Bind to Penicillin Binding Proteins Enzymes involved in cell wall synthesis Activity of an Antibiotic
More informationORIGINAL ARTICLE /j x. Mallorca, Spain
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01251.x Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More information